TenX Keane Acquisition Ordinary Share (TENK)
| Market Cap | 73.98M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 6.65M |
| EPS (ttm) | 0.27 |
| PE Ratio | 41.19 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4 |
| Open | 11.12 |
| Previous Close | 11.13 |
| Day's Range | 11.12 - 11.13 |
| 52-Week Range | 10.41 - 12.03 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About TENK
TenX Keane Acquisition focuses on effecting a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on target businesses operating in Asia, excluding companies located or operating in mainland China, Hong Kong, or Macau. The company was incorporated in 2021 and is based in New York, New York. [Read more]
Financial Performance
Financial StatementsNews
TenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment Proposal
New York, NY, Jan. 10, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (Nasdaq: TENKU, TENK, TENKR) (the “Company”), announced today that if the proposal to amend the Company's Amended and Restated Me...
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024 LYMPHIR™ BLA resubmission on track for early 2024 CRANFORD, N.J. , Jan. 2, 2024 /PRNewswire/ -- Citius Pharmaceutica...
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post transaction Transact...
TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business Combination
New York, NY, Oct. 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (NASDAQ: TENKU) today announced that, in order to extend the date by which the Company must complete its initial ...
TenX Keane Acquisition Announces the Separate Trading of its Ordinary Shares and Rights Commencing on December 8, 2022
New York, NY, Dec. 06, 2022 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”) (Nasdaq: TENKU), a newly incorporated blank check company, today announced that, commencing on December 8, 2022, ...
TenX Keane Acquisition Announces Closing of $66 Million Initial Public Offering, Including Partial Exercise of Underwriter's Over-Allotment Option
New York, Oct. 18, 2022 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU) (the “Company”), a newly incorporated blank check company incorporated as a Cayman Islands exempted company formed for...
TenX Keane Acquisition Announces Pricing of $60 Million Initial Public Offering
New York, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the “Company”), a newly incorporated blank check company incorporated as a Cayman Islands exempted company formed for the purpose of...